In order to prevent spam,
this email address cannot be copied.
Member Profile - Andrew Sutton Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Community: Member Directory
Member Profile

Member Information
First Name:Andrew
Last Name:Sutton
Title:Dr
Advanced Degrees:MD(London.UK), FFA
Affiliation:None (ex Medical Director Regen Therapeutics)
Street Address 1:4,
Street Address 2:Elmleigh
City:Midhurst,
State/Province:West Sussex
Zip/Postal Code:GU29 9HA
Country/Territory:United Kingdom
Phone:01730817150
Email Address: 
Disclosure:
(view policy)  		Member reports the following financial or other potential conflicts of interest: [Last Modified: 19 January 2012]

I am a retired medical director of ReGen Therapeutics plc (www.regentherapeutics.com) and have a small stock holding in that company. It has patents on Colostrinin(R) a nutraceutical with activity in Alzheimer's Disease and the proven effect of zolpidem in reversing effects of brain damage. I try to raise awareness of these 2 safe and effective treatments that could have tremendous benefits but are languishing because ReGen ran out of money.
View all comments by Andrew Sutton
Clinical Interests:
Aging Process, Stroke and Trauma, Alzheimer Disease
Research Focus:
Drug screening, peptides, Clinical trials

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad